| Authors: |
Singh PN; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Hadj Bachir E; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Howe JR; Department of Surgery and., Bellizzi AM; Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA., Cejas P; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Madha-Krause S; Department of Medical Oncology and., Epstein CB; Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA., Chan JA; Department of Medical Oncology and.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Bernstein B; Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA., Kulke MH; Department of Medical Oncology and.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Zhou Q; Division of Regenerative Medicine and Hartman Institute for Therapeutic Organ Regeneration, Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Shivdasani RA; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. |
